Ipamorelin is a synthetic growth hormone–releasing peptide studied for its highly selective stimulation of GH secretion — with minimal effects on cortisol, prolactin, or appetite compared to earlier compounds in its class. Here is what the research shows about how it works and what patients should know.
Unlike many growth hormone secretagogues, ipamorelin was designed specifically to avoid the side-effect profile of earlier peptides in its class. It does not trigger meaningful cortisol or prolactin release at standard doses, which has made it one of the more studied peptides in the growth hormone axis category. This article covers the mechanism, the research, dosing principles, and what a provider evaluation would assess before prescribing ipamorelin as part of a compounded peptide protocol. Note: ipamorelin is not FDA-approved.
What Is Ipamorelin and How Does It Work?
Ipamorelin is a pentapeptide (five amino acid chain) that acts as a selective agonist at the growth hormone secretagogue receptor (GHSR-1a), also called the ghrelin receptor. Unlike ghrelin itself, ipamorelin does not produce the same appetite-stimulating or cortisol-releasing effects, despite binding to the same receptor subtype.
The mechanism works in two steps:
- GHRH amplification: Ipamorelin binds GHSR-1a in the pituitary and hypothalamus, augmenting the natural GHRH (growth hormone–releasing hormone) pulse.
- Somatostatin suppression: It transiently reduces somatostatin tone — the inhibitory signal that limits GH release between pulses.
The result is an amplified, pulsatile GH release that mimics the body's natural secretory pattern rather than producing a continuous supraphysiologic GH surge. This pulsatile pattern is considered important for maintaining downstream effects including IGF-1 production in the liver, which drives many of ipamorelin's studied benefits.
Ipamorelin vs. Other Growth Hormone Peptides
| Peptide | Mechanism | Half-Life | Cortisol Spike | Appetite Effect |
|---|---|---|---|---|
| Ipamorelin | Selective GHSR-1a agonist | ~2 hours | Minimal | Minimal |
| GHRP-2 | GHSR-1a agonist | ~30 minutes | Moderate | Moderate |
| GHRP-6 | GHSR-1a agonist | ~30 minutes | Moderate | Strong |
| Hexarelin | GHSR-1a agonist (potent) | ~2 hours | High | Moderate |
| CJC-1295 | GHRH analog | Days (DAC form) | Low | Minimal |
Ipamorelin's selectivity profile — particularly its low cortisol and appetite activity — is the primary reason it is commonly combined with CJC-1295 rather than used with GHRP-2 or GHRP-6. The combination produces synergistic GH release (acting on both the GHRH and secretagogue pathways simultaneously) without compounding unwanted hormonal side effects. Read the research on the CJC-1295 + ipamorelin stack.
What Research Shows About Ipamorelin's Benefits
The foundational pharmacology of ipamorelin was described by Raun et al. (1998), who characterized it as the first truly selective GH secretagogue — producing GH secretion comparable to earlier GHRPs while significantly reducing cortisol and prolactin co-secretion. This selectivity profile has driven most subsequent clinical interest in the compound.
Research in animal models and early human pharmacology studies has identified the following potential areas of activity:
- Body composition: GH stimulation is associated with increased lipolysis (fat mobilization) and support for lean mass preservation, though these effects in the context of ipamorelin specifically have been studied primarily in preclinical models.
- Sleep quality: GH secretion is predominantly nocturnal and tied to slow-wave sleep. Some patients using GH-stimulating peptides report improved sleep quality, consistent with the known relationship between GH pulses and sleep architecture.
- Recovery: Growth hormone signaling supports tissue repair via IGF-1 pathways. Early research suggested potential benefits for post-exercise recovery and soft tissue healing, though controlled human trials are limited.
- Bone density: GH and IGF-1 are key regulators of bone remodeling. Sustained GH stimulation over time may support bone mineral density, though long-term human data for ipamorelin specifically is not well established.
For a broader view of the GH secretagogue research, Examine's ipamorelin summary aggregates available evidence with quality ratings.
Important limitation: most human data involves GH secretagogue analogs generally, not ipamorelin in isolation. Extrapolating findings from GH administration trials or GHRP-2/6 studies to ipamorelin requires care. A provider can help contextualize the evidence relative to your specific health goals. Approval for any compounded peptide protocol is subject to provider evaluation and is not guaranteed.
Dosage, Timing and Administration
Ipamorelin is typically administered via subcutaneous injection. Principles commonly discussed in the clinical literature include:
- Timing: Administered 1–3 times daily, typically at bedtime to align with the natural nocturnal GH pulse, and/or peri-workout in protocols combining body composition goals.
- Fasting state: GH secretion is blunted by postprandial insulin levels. Injections are generally administered in a fasted or near-fasted state for optimal GH pulse amplitude.
- Cycling: Protocols commonly include cycling periods (e.g., 3 months on, 1 month off) to prevent downregulation of GHSR-1a receptor sensitivity, though the optimal cycling schedule has not been established in controlled human trials.
These are general pharmacological principles. Actual dosing, timing, and cycling parameters for any patient would be determined by the prescribing provider based on individual labs, health status, and goals. Compare ipamorelin to sermorelin for additional context on the GH peptide category. You can also review the research on MK-677, an oral GH secretagogue with a different mechanism profile.
Side Effects and Who Should Avoid Ipamorelin
Ipamorelin's selectivity profile means it carries fewer off-target effects than earlier GHRPs, but it is not side-effect free:
- Common (mild): Transient flushing, tingling, or warmth; mild headache shortly after injection related to GH pulse; water retention in some patients at higher doses.
- Potential concern: Any GH-stimulating agent may theoretically accelerate growth in hormonally active tissue. Patients with active or history of hormone-sensitive cancers should not use GH-stimulating peptides without careful oncological review.
- Contraindications: Active malignancy; pregnancy or breastfeeding; patients with untreated pituitary pathology; pediatric use.
Because ipamorelin operates through the GH axis, baseline labs — at minimum IGF-1 levels — are recommended before initiating therapy and during monitoring to ensure GH stimulation remains within physiologic range.
Frequently Asked Questions
Is ipamorelin FDA-approved?
No. Ipamorelin is not FDA-approved for any indication. It is available as a compounded medication prepared under federal compounding regulations. Compounded formulations are not equivalent to FDA-approved products.
How long does it take to see results from ipamorelin?
IGF-1 levels typically begin to rise within 4–6 weeks of consistent use. Body composition changes, if they occur, are generally observed over 3–6 months of sustained protocol use. Individual response varies significantly based on baseline GH status, diet, training, sleep, and other factors.
Can ipamorelin be used alone or does it need to be combined with CJC-1295?
Ipamorelin can be used as a standalone peptide. However, combining it with a GHRH analog like CJC-1295 is common in clinical practice because the two peptides work on complementary pathways, producing synergistic GH release without compounding side effects. Your provider would determine the appropriate protocol based on your labs and goals.
Does ipamorelin increase cortisol?
At standard doses, ipamorelin produces minimal cortisol elevation compared to earlier GHRPs like GHRP-2 or GHRP-6. This is one of its defining pharmacological characteristics. Some cortisol co-secretion may occur at higher doses.
Who is a candidate for ipamorelin therapy?
Candidacy is determined by a licensed provider based on labs (including IGF-1), symptoms, health history, and goals. General areas of clinical interest include adults with suboptimal GH secretion, sleep disruption, body composition challenges, or recovery limitations. Approval is not guaranteed and is subject to provider evaluation.
Is ipamorelin the same as HGH (human growth hormone)?
No. Ipamorelin stimulates the body's own GH secretion through receptor signaling — it does not supply exogenous GH directly. HGH (injectable human growth hormone) is a Schedule III controlled substance requiring a separate category of evaluation and prescription. GH secretagogues like ipamorelin work indirectly through the pituitary axis.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.